We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.13 | 2.72% | 42.5692 | 42.84 | 42.275 | 42.70 | 4,686,149 | 00:13:18 |
From May 2019 to May 2024
By Ian Walker
LONDON--GlaxoSmithKline PLC (GSK.LN) on Wednesday said it has filed regulatory submissions in the U.S. and Europe seeking approval for mepolizumab as a maintenance treatment for patients with severe eosinophilic asthma.
The pharmaceutical giant also said regulatory filings are planned in other countries during the rest of 2014 and 2015. Mepolizumab is not currently approved for use anywhere in the world, it added.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
